Risk and burden associated with the acquisition of viral hepatitis A and B in the corporate traveler.
As the number of international business travelers continues to grow, so does the list of destinations, many of which are endemic for both hepatitis A and B. Generally, travelers are unaware of the risks of acquiring viral hepatitis when traveling; many are unsure of modes of transmission and do not seek pretravel advice or do not follow the recommendations of travel health professionals. Infected employees can result in increased health care costs and reduced productivity in the workplace. Safe and efficacious monovalent vaccines and a combined hepatitis A and B vaccine are available. Successful corporate health and immunization programs can prevent hepatitis A and B when employees are abroad on business. This article examines the distribution, risks, costs, burden, and prevention of hepatitis A and B in the international business traveler.
Bunn
William B
WB
International Truck and Engine Corporation, 4201 Winfield Road, Warrenville, IL 60555, USA. william.bunn@navistar.com
D003132:Commerce; D019353:Endemic Diseases / Q000191:economics / Q000517:prevention & control*; D017048:Health Care Costs; D007722:Health Knowledge, Attitudes, Practice; D006506:Hepatitis A / Q000191:economics / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000627:therapeutic use; D006509:Hepatitis B / Q000191:economics / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006801:Humans; D016272:Occupational Health; D009786:Occupational Health Services / Q000191:economics; D012307:Risk Factors; D014195:Travel
D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines